Chapter/Section Purchase

1 Study Coverage
1.1 Tumor Necrosis Factor Inhibitors Product Introduction
1.2 Market by Type
1.2.1 Global Tumor Necrosis Factor Inhibitors Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Humira
1.2.3 Enbrel
1.2.4 Remicade
1.2.5 Others
1.3 Market by Application
1.3.1 Global Tumor Necrosis Factor Inhibitors Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Alzheimer's Diseases
1.3.3 Parkinson's Diseases
1.3.4 Ischemic Stroke
1.3.5 Multiple Sclerosis
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Tumor Necrosis Factor Inhibitors Sales Estimates and Forecasts 2017-2028
2.2 Global Tumor Necrosis Factor Inhibitors Revenue Estimates and Forecasts 2017-2028
2.3 Global Tumor Necrosis Factor Inhibitors Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Tumor Necrosis Factor Inhibitors Sales by Region
2.4.1 Global Tumor Necrosis Factor Inhibitors Sales by Region (2017-2022)
2.4.2 Global Sales Tumor Necrosis Factor Inhibitors by Region (2023-2028)
2.5 Global Tumor Necrosis Factor Inhibitors Revenue by Region
2.5.1 Global Tumor Necrosis Factor Inhibitors Revenue by Region (2017-2022)
2.5.2 Global Tumor Necrosis Factor Inhibitors Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Tumor Necrosis Factor Inhibitors Sales by Manufacturers
3.1.1 Global Top Tumor Necrosis Factor Inhibitors Manufacturers by Sales (2017-2022)
3.1.2 Global Tumor Necrosis Factor Inhibitors Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Tumor Necrosis Factor Inhibitors in 2021
3.2 Global Tumor Necrosis Factor Inhibitors Revenue by Manufacturers
3.2.1 Global Tumor Necrosis Factor Inhibitors Revenue by Manufacturers (2017-2022)
3.2.2 Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Tumor Necrosis Factor Inhibitors Revenue in 2021
3.3 Global Tumor Necrosis Factor Inhibitors Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Tumor Necrosis Factor Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Tumor Necrosis Factor Inhibitors Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Tumor Necrosis Factor Inhibitors Sales by Type
4.1.1 Global Tumor Necrosis Factor Inhibitors Historical Sales by Type (2017-2022)
4.1.2 Global Tumor Necrosis Factor Inhibitors Forecasted Sales by Type (2023-2028)
4.1.3 Global Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2017-2028)
4.2 Global Tumor Necrosis Factor Inhibitors Revenue by Type
4.2.1 Global Tumor Necrosis Factor Inhibitors Historical Revenue by Type (2017-2022)
4.2.2 Global Tumor Necrosis Factor Inhibitors Forecasted Revenue by Type (2023-2028)
4.2.3 Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Type (2017-2028)
4.3 Global Tumor Necrosis Factor Inhibitors Price by Type
4.3.1 Global Tumor Necrosis Factor Inhibitors Price by Type (2017-2022)
4.3.2 Global Tumor Necrosis Factor Inhibitors Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Tumor Necrosis Factor Inhibitors Sales by Application
5.1.1 Global Tumor Necrosis Factor Inhibitors Historical Sales by Application (2017-2022)
5.1.2 Global Tumor Necrosis Factor Inhibitors Forecasted Sales by Application (2023-2028)
5.1.3 Global Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2017-2028)
5.2 Global Tumor Necrosis Factor Inhibitors Revenue by Application
5.2.1 Global Tumor Necrosis Factor Inhibitors Historical Revenue by Application (2017-2022)
5.2.2 Global Tumor Necrosis Factor Inhibitors Forecasted Revenue by Application (2023-2028)
5.2.3 Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Application (2017-2028)
5.3 Global Tumor Necrosis Factor Inhibitors Price by Application
5.3.1 Global Tumor Necrosis Factor Inhibitors Price by Application (2017-2022)
5.3.2 Global Tumor Necrosis Factor Inhibitors Price Forecast by Application (2023-2028)
6 North America
6.1 North America Tumor Necrosis Factor Inhibitors Market Size by Type
6.1.1 North America Tumor Necrosis Factor Inhibitors Sales by Type (2017-2028)
6.1.2 North America Tumor Necrosis Factor Inhibitors Revenue by Type (2017-2028)
6.2 North America Tumor Necrosis Factor Inhibitors Market Size by Application
6.2.1 North America Tumor Necrosis Factor Inhibitors Sales by Application (2017-2028)
6.2.2 North America Tumor Necrosis Factor Inhibitors Revenue by Application (2017-2028)
6.3 North America Tumor Necrosis Factor Inhibitors Market Size by Country
6.3.1 North America Tumor Necrosis Factor Inhibitors Sales by Country (2017-2028)
6.3.2 North America Tumor Necrosis Factor Inhibitors Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Tumor Necrosis Factor Inhibitors Market Size by Type
7.1.1 Europe Tumor Necrosis Factor Inhibitors Sales by Type (2017-2028)
7.1.2 Europe Tumor Necrosis Factor Inhibitors Revenue by Type (2017-2028)
7.2 Europe Tumor Necrosis Factor Inhibitors Market Size by Application
7.2.1 Europe Tumor Necrosis Factor Inhibitors Sales by Application (2017-2028)
7.2.2 Europe Tumor Necrosis Factor Inhibitors Revenue by Application (2017-2028)
7.3 Europe Tumor Necrosis Factor Inhibitors Market Size by Country
7.3.1 Europe Tumor Necrosis Factor Inhibitors Sales by Country (2017-2028)
7.3.2 Europe Tumor Necrosis Factor Inhibitors Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Tumor Necrosis Factor Inhibitors Market Size by Type
8.1.1 Asia Pacific Tumor Necrosis Factor Inhibitors Sales by Type (2017-2028)
8.1.2 Asia Pacific Tumor Necrosis Factor Inhibitors Revenue by Type (2017-2028)
8.2 Asia Pacific Tumor Necrosis Factor Inhibitors Market Size by Application
8.2.1 Asia Pacific Tumor Necrosis Factor Inhibitors Sales by Application (2017-2028)
8.2.2 Asia Pacific Tumor Necrosis Factor Inhibitors Revenue by Application (2017-2028)
8.3 Asia Pacific Tumor Necrosis Factor Inhibitors Market Size by Region
8.3.1 Asia Pacific Tumor Necrosis Factor Inhibitors Sales by Region (2017-2028)
8.3.2 Asia Pacific Tumor Necrosis Factor Inhibitors Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Tumor Necrosis Factor Inhibitors Market Size by Type
9.1.1 Latin America Tumor Necrosis Factor Inhibitors Sales by Type (2017-2028)
9.1.2 Latin America Tumor Necrosis Factor Inhibitors Revenue by Type (2017-2028)
9.2 Latin America Tumor Necrosis Factor Inhibitors Market Size by Application
9.2.1 Latin America Tumor Necrosis Factor Inhibitors Sales by Application (2017-2028)
9.2.2 Latin America Tumor Necrosis Factor Inhibitors Revenue by Application (2017-2028)
9.3 Latin America Tumor Necrosis Factor Inhibitors Market Size by Country
9.3.1 Latin America Tumor Necrosis Factor Inhibitors Sales by Country (2017-2028)
9.3.2 Latin America Tumor Necrosis Factor Inhibitors Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Market Size by Type
10.1.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Sales by Type (2017-2028)
10.1.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue by Type (2017-2028)
10.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Market Size by Application
10.2.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Sales by Application (2017-2028)
10.2.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue by Application (2017-2028)
10.3 Middle East and Africa Tumor Necrosis Factor Inhibitors Market Size by Country
10.3.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Sales by Country (2017-2028)
10.3.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 EPIRUS Biopharmaceuticals
11.1.1 EPIRUS Biopharmaceuticals Corporation Information
11.1.2 EPIRUS Biopharmaceuticals Overview
11.1.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 EPIRUS Biopharmaceuticals Recent Developments
11.2 Bionovis
11.2.1 Bionovis Corporation Information
11.2.2 Bionovis Overview
11.2.3 Bionovis Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Bionovis Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Bionovis Recent Developments
11.3 CASI Pharmaceuticals
11.3.1 CASI Pharmaceuticals Corporation Information
11.3.2 CASI Pharmaceuticals Overview
11.3.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 CASI Pharmaceuticals Recent Developments
11.4 Janssen Biotech
11.4.1 Janssen Biotech Corporation Information
11.4.2 Janssen Biotech Overview
11.4.3 Janssen Biotech Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Janssen Biotech Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Janssen Biotech Recent Developments
11.5 Momenta Pharmaceuticals
11.5.1 Momenta Pharmaceuticals Corporation Information
11.5.2 Momenta Pharmaceuticals Overview
11.5.3 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Momenta Pharmaceuticals Recent Developments
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Corporation Information
11.6.2 GlaxoSmithKline Overview
11.6.3 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 GlaxoSmithKline Recent Developments
11.7 HanAll Biopharma
11.7.1 HanAll Biopharma Corporation Information
11.7.2 HanAll Biopharma Overview
11.7.3 HanAll Biopharma Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 HanAll Biopharma Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 HanAll Biopharma Recent Developments
11.8 Intas Pharmaceuticals
11.8.1 Intas Pharmaceuticals Corporation Information
11.8.2 Intas Pharmaceuticals Overview
11.8.3 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Intas Pharmaceuticals Recent Developments
11.9 LEO Pharma
11.9.1 LEO Pharma Corporation Information
11.9.2 LEO Pharma Overview
11.9.3 LEO Pharma Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 LEO Pharma Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 LEO Pharma Recent Developments
11.10 Dexa Medica
11.10.1 Dexa Medica Corporation Information
11.10.2 Dexa Medica Overview
11.10.3 Dexa Medica Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Dexa Medica Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Dexa Medica Recent Developments
11.11 LG Life Sciences
11.11.1 LG Life Sciences Corporation Information
11.11.2 LG Life Sciences Overview
11.11.3 LG Life Sciences Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 LG Life Sciences Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 LG Life Sciences Recent Developments
11.12 MedImmune
11.12.1 MedImmune Corporation Information
11.12.2 MedImmune Overview
11.12.3 MedImmune Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 MedImmune Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 MedImmune Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Tumor Necrosis Factor Inhibitors Industry Chain Analysis
12.2 Tumor Necrosis Factor Inhibitors Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Tumor Necrosis Factor Inhibitors Production Mode & Process
12.4 Tumor Necrosis Factor Inhibitors Sales and Marketing
12.4.1 Tumor Necrosis Factor Inhibitors Sales Channels
12.4.2 Tumor Necrosis Factor Inhibitors Distributors
12.5 Tumor Necrosis Factor Inhibitors Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Tumor Necrosis Factor Inhibitors Industry Trends
13.2 Tumor Necrosis Factor Inhibitors Market Drivers
13.3 Tumor Necrosis Factor Inhibitors Market Challenges
13.4 Tumor Necrosis Factor Inhibitors Market Restraints
14 Key Findings in The Global Tumor Necrosis Factor Inhibitors Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer